First American Bank Has $588,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

First American Bank lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 4,403 shares of the life sciences company’s stock after selling 405 shares during the period. First American Bank’s holdings in Illumina were worth $588,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of ILMN. QRG Capital Management Inc. increased its holdings in shares of Illumina by 35.1% in the fourth quarter. QRG Capital Management Inc. now owns 11,365 shares of the life sciences company’s stock valued at $1,519,000 after purchasing an additional 2,954 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Illumina in the fourth quarter worth about $10,875,000. Oppenheimer Asset Management Inc. bought a new position in shares of Illumina in the fourth quarter worth about $901,000. Mn Services Vermogensbeheer B.V. raised its holdings in Illumina by 1.6% in the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 61,900 shares of the life sciences company’s stock valued at $8,272,000 after buying an additional 1,000 shares during the last quarter. Finally, Whipplewood Advisors LLC bought a new position in Illumina in the 4th quarter valued at approximately $137,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 5.4 %

ILMN stock opened at $88.97 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $14.09 billion, a PE ratio of -11.58, a PEG ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a twelve month low of $88.75 and a twelve month high of $156.66. The stock has a 50-day simple moving average of $124.32 and a two-hundred day simple moving average of $133.21.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ILMN shares. Canaccord Genuity Group decreased their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. UBS Group increased their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Citigroup downgraded shares of Illumina from a “buy” rating to a “neutral” rating and decreased their target price for the company from $190.00 to $165.00 in a research report on Wednesday, December 11th. Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and reduced their price objective for the stock from $130.00 to $100.00 in a research report on Monday, February 10th. Finally, Piper Sandler raised their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $159.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.